Review





Similar Products

96
MedChemExpress dexamethasone
Dexamethasone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexamethasone/product/MedChemExpress
Average 96 stars, based on 1 article reviews
dexamethasone - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

96
Thermo Fisher n ethylmaleimide
a. Schematic depicting the chemical proteomic workflow for profiling oxidized cysteines. Cells are treated <t>with</t> <t>N-ethylmaleimide</t> (NEM) before lysis and Iodoacetamide (IAM) after lysis to alkylate the reduced cysteines and GSH. Oxidized cysteines are reduced by Tris(2-carboxyethyl) phosphine (TCEP) before being labeled with iodoacetamide-desthiobiotin (IA-DTB) and enrichment via streptavidin agarose beads for further tandem mass tag (TMT) labeling and LC/LC-MS/MS/MS analysis. b. Bar graph representing the percent of proteins within indicated organelles showing higher than 1.5-fold difference (log 2 ) in reactivity of oxidized cysteines from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. c. Fold change (log 2 ) in oxidized cysteine reactivity of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. Dark red and light red mark cysteine residues with ≥2-fold and ≥1.5-fold reactivity changes compared to protein expression, respectively. Grey marks unchanged cysteines. Green marks protein expression. Data are median values for n = 2 (or more) independent cysteine reactivity profiling experiments and n = 1 independent unenriched proteomics experiments. Each biological independent experiment had 2-3 technical replicates for each condition. d. Immunoblot analysis of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) modified proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were reduced with 10 mM DTT or oxidized with 5 mM diamide for 5 minutes prior to treatment with 25 mM NEM for 10 minutes before lysis. The bands of oxidized and reduced proteins are labeled. e. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control (EV), WT or 2YA mutant SLC33A1 cDNAs. f. Immunoblot analysis of indicated proteins from SLC33A1 knockout HEK293T cells expressing an inducible cyto-GshF (icyto-GshF) complemented with a vector control WT or 2YA mutant SLC33A1 cDNA treated with 1 µg/ml doxycycline for 48 hours. g. Heatmap of fold change (log 2 ) in unfolded protein response (UPR) target mRNAs from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA comparing cells treated with tunicamycin to DMSO. Cells were treated with DMSO or 10 ng/ml tunicamycin (TM) for 8 hours before RNA extraction. h. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were treated with 20 ng/ml tunicamycin for indicated time. i. Left, percent of cell number from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Right, percent of cell number from SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Numbers under tunicamycin treatment were normalized to DMSO untreated. j. Relative metabolite abundance of indicated whole cell or ER metabolites from Slc33a1 knockout KPK cells expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la . k. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la. l. Left, CRISPR gene scores in SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA cultured for 14 doublings. Top scoring hits color-coded. Pearson correlation coefficient, two-sided. Right, top-scoring genes that sensitize cells to SLC33A1 loss. m. Percent of cell number from SLC33A1 knockout HEK293T cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting SYVN1 after 4-day proliferation. Numbers of sg SYVN1 were normalized to sgCtr. n. Schematic of GSSG export by SLC33A1 to maintain ER redox homeostasis. GSH imported into ER is oxidized to GSSG upon reducing PDI family proteins that catalyze disulfide reduction and isomerization. SLC33A1 exports GSSG into cytosol, where it is reduced back to GSH by glutathione reductase (GR).
N Ethylmaleimide, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n ethylmaleimide/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
n ethylmaleimide - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

96
MedChemExpress hy 14648 vincristine sulfate mce
a. Schematic depicting the chemical proteomic workflow for profiling oxidized cysteines. Cells are treated <t>with</t> <t>N-ethylmaleimide</t> (NEM) before lysis and Iodoacetamide (IAM) after lysis to alkylate the reduced cysteines and GSH. Oxidized cysteines are reduced by Tris(2-carboxyethyl) phosphine (TCEP) before being labeled with iodoacetamide-desthiobiotin (IA-DTB) and enrichment via streptavidin agarose beads for further tandem mass tag (TMT) labeling and LC/LC-MS/MS/MS analysis. b. Bar graph representing the percent of proteins within indicated organelles showing higher than 1.5-fold difference (log 2 ) in reactivity of oxidized cysteines from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. c. Fold change (log 2 ) in oxidized cysteine reactivity of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. Dark red and light red mark cysteine residues with ≥2-fold and ≥1.5-fold reactivity changes compared to protein expression, respectively. Grey marks unchanged cysteines. Green marks protein expression. Data are median values for n = 2 (or more) independent cysteine reactivity profiling experiments and n = 1 independent unenriched proteomics experiments. Each biological independent experiment had 2-3 technical replicates for each condition. d. Immunoblot analysis of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) modified proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were reduced with 10 mM DTT or oxidized with 5 mM diamide for 5 minutes prior to treatment with 25 mM NEM for 10 minutes before lysis. The bands of oxidized and reduced proteins are labeled. e. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control (EV), WT or 2YA mutant SLC33A1 cDNAs. f. Immunoblot analysis of indicated proteins from SLC33A1 knockout HEK293T cells expressing an inducible cyto-GshF (icyto-GshF) complemented with a vector control WT or 2YA mutant SLC33A1 cDNA treated with 1 µg/ml doxycycline for 48 hours. g. Heatmap of fold change (log 2 ) in unfolded protein response (UPR) target mRNAs from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA comparing cells treated with tunicamycin to DMSO. Cells were treated with DMSO or 10 ng/ml tunicamycin (TM) for 8 hours before RNA extraction. h. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were treated with 20 ng/ml tunicamycin for indicated time. i. Left, percent of cell number from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Right, percent of cell number from SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Numbers under tunicamycin treatment were normalized to DMSO untreated. j. Relative metabolite abundance of indicated whole cell or ER metabolites from Slc33a1 knockout KPK cells expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la . k. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la. l. Left, CRISPR gene scores in SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA cultured for 14 doublings. Top scoring hits color-coded. Pearson correlation coefficient, two-sided. Right, top-scoring genes that sensitize cells to SLC33A1 loss. m. Percent of cell number from SLC33A1 knockout HEK293T cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting SYVN1 after 4-day proliferation. Numbers of sg SYVN1 were normalized to sgCtr. n. Schematic of GSSG export by SLC33A1 to maintain ER redox homeostasis. GSH imported into ER is oxidized to GSSG upon reducing PDI family proteins that catalyze disulfide reduction and isomerization. SLC33A1 exports GSSG into cytosol, where it is reduced back to GSH by glutathione reductase (GR).
Hy 14648 Vincristine Sulfate Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 14648 vincristine sulfate mce/product/MedChemExpress
Average 96 stars, based on 1 article reviews
hy 14648 vincristine sulfate mce - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

94
MedChemExpress hy 17420 dexamethasone mce
a. Schematic depicting the chemical proteomic workflow for profiling oxidized cysteines. Cells are treated <t>with</t> <t>N-ethylmaleimide</t> (NEM) before lysis and Iodoacetamide (IAM) after lysis to alkylate the reduced cysteines and GSH. Oxidized cysteines are reduced by Tris(2-carboxyethyl) phosphine (TCEP) before being labeled with iodoacetamide-desthiobiotin (IA-DTB) and enrichment via streptavidin agarose beads for further tandem mass tag (TMT) labeling and LC/LC-MS/MS/MS analysis. b. Bar graph representing the percent of proteins within indicated organelles showing higher than 1.5-fold difference (log 2 ) in reactivity of oxidized cysteines from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. c. Fold change (log 2 ) in oxidized cysteine reactivity of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. Dark red and light red mark cysteine residues with ≥2-fold and ≥1.5-fold reactivity changes compared to protein expression, respectively. Grey marks unchanged cysteines. Green marks protein expression. Data are median values for n = 2 (or more) independent cysteine reactivity profiling experiments and n = 1 independent unenriched proteomics experiments. Each biological independent experiment had 2-3 technical replicates for each condition. d. Immunoblot analysis of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) modified proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were reduced with 10 mM DTT or oxidized with 5 mM diamide for 5 minutes prior to treatment with 25 mM NEM for 10 minutes before lysis. The bands of oxidized and reduced proteins are labeled. e. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control (EV), WT or 2YA mutant SLC33A1 cDNAs. f. Immunoblot analysis of indicated proteins from SLC33A1 knockout HEK293T cells expressing an inducible cyto-GshF (icyto-GshF) complemented with a vector control WT or 2YA mutant SLC33A1 cDNA treated with 1 µg/ml doxycycline for 48 hours. g. Heatmap of fold change (log 2 ) in unfolded protein response (UPR) target mRNAs from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA comparing cells treated with tunicamycin to DMSO. Cells were treated with DMSO or 10 ng/ml tunicamycin (TM) for 8 hours before RNA extraction. h. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were treated with 20 ng/ml tunicamycin for indicated time. i. Left, percent of cell number from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Right, percent of cell number from SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Numbers under tunicamycin treatment were normalized to DMSO untreated. j. Relative metabolite abundance of indicated whole cell or ER metabolites from Slc33a1 knockout KPK cells expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la . k. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la. l. Left, CRISPR gene scores in SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA cultured for 14 doublings. Top scoring hits color-coded. Pearson correlation coefficient, two-sided. Right, top-scoring genes that sensitize cells to SLC33A1 loss. m. Percent of cell number from SLC33A1 knockout HEK293T cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting SYVN1 after 4-day proliferation. Numbers of sg SYVN1 were normalized to sgCtr. n. Schematic of GSSG export by SLC33A1 to maintain ER redox homeostasis. GSH imported into ER is oxidized to GSSG upon reducing PDI family proteins that catalyze disulfide reduction and isomerization. SLC33A1 exports GSSG into cytosol, where it is reduced back to GSH by glutathione reductase (GR).
Hy 17420 Dexamethasone Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 17420 dexamethasone mce/product/MedChemExpress
Average 94 stars, based on 1 article reviews
hy 17420 dexamethasone mce - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

95
Valiant Co Ltd osteogenic induction reagents
Characterization and differentiation potential of hPDLCs. (A) Schematic representation of hPDLCs mechanical memory, including the experimental grouping of cells cultured on substrates with soft (So) and stiff (St) matrix stiffness to evaluate mechanical memory effects. (B) Flow cytometry identification of hPDLCs using cell surface markers (presence of mesenchymal markers CD90 and CD146 and absence of hematopoietic markers CD34 and CD45). (C) The representative images of hPDLCs lipogenic ability. (D) The representative images of hPDLCs <t>osteogenic</t> ability. Scale bars in (c) = 50 μm, in (d) = 200 μm.
Osteogenic Induction Reagents, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/osteogenic induction reagents/product/Valiant Co Ltd
Average 95 stars, based on 1 article reviews
osteogenic induction reagents - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

96
MedChemExpress hy-14648
Characterization and differentiation potential of hPDLCs. (A) Schematic representation of hPDLCs mechanical memory, including the experimental grouping of cells cultured on substrates with soft (So) and stiff (St) matrix stiffness to evaluate mechanical memory effects. (B) Flow cytometry identification of hPDLCs using cell surface markers (presence of mesenchymal markers CD90 and CD146 and absence of hematopoietic markers CD34 and CD45). (C) The representative images of hPDLCs lipogenic ability. (D) The representative images of hPDLCs <t>osteogenic</t> ability. Scale bars in (c) = 50 μm, in (d) = 200 μm.
Hy 14648, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy-14648/product/MedChemExpress
Average 96 stars, based on 1 article reviews
hy-14648 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


a. Schematic depicting the chemical proteomic workflow for profiling oxidized cysteines. Cells are treated with N-ethylmaleimide (NEM) before lysis and Iodoacetamide (IAM) after lysis to alkylate the reduced cysteines and GSH. Oxidized cysteines are reduced by Tris(2-carboxyethyl) phosphine (TCEP) before being labeled with iodoacetamide-desthiobiotin (IA-DTB) and enrichment via streptavidin agarose beads for further tandem mass tag (TMT) labeling and LC/LC-MS/MS/MS analysis. b. Bar graph representing the percent of proteins within indicated organelles showing higher than 1.5-fold difference (log 2 ) in reactivity of oxidized cysteines from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. c. Fold change (log 2 ) in oxidized cysteine reactivity of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. Dark red and light red mark cysteine residues with ≥2-fold and ≥1.5-fold reactivity changes compared to protein expression, respectively. Grey marks unchanged cysteines. Green marks protein expression. Data are median values for n = 2 (or more) independent cysteine reactivity profiling experiments and n = 1 independent unenriched proteomics experiments. Each biological independent experiment had 2-3 technical replicates for each condition. d. Immunoblot analysis of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) modified proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were reduced with 10 mM DTT or oxidized with 5 mM diamide for 5 minutes prior to treatment with 25 mM NEM for 10 minutes before lysis. The bands of oxidized and reduced proteins are labeled. e. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control (EV), WT or 2YA mutant SLC33A1 cDNAs. f. Immunoblot analysis of indicated proteins from SLC33A1 knockout HEK293T cells expressing an inducible cyto-GshF (icyto-GshF) complemented with a vector control WT or 2YA mutant SLC33A1 cDNA treated with 1 µg/ml doxycycline for 48 hours. g. Heatmap of fold change (log 2 ) in unfolded protein response (UPR) target mRNAs from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA comparing cells treated with tunicamycin to DMSO. Cells were treated with DMSO or 10 ng/ml tunicamycin (TM) for 8 hours before RNA extraction. h. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were treated with 20 ng/ml tunicamycin for indicated time. i. Left, percent of cell number from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Right, percent of cell number from SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Numbers under tunicamycin treatment were normalized to DMSO untreated. j. Relative metabolite abundance of indicated whole cell or ER metabolites from Slc33a1 knockout KPK cells expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la . k. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la. l. Left, CRISPR gene scores in SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA cultured for 14 doublings. Top scoring hits color-coded. Pearson correlation coefficient, two-sided. Right, top-scoring genes that sensitize cells to SLC33A1 loss. m. Percent of cell number from SLC33A1 knockout HEK293T cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting SYVN1 after 4-day proliferation. Numbers of sg SYVN1 were normalized to sgCtr. n. Schematic of GSSG export by SLC33A1 to maintain ER redox homeostasis. GSH imported into ER is oxidized to GSSG upon reducing PDI family proteins that catalyze disulfide reduction and isomerization. SLC33A1 exports GSSG into cytosol, where it is reduced back to GSH by glutathione reductase (GR).

Journal: bioRxiv

Article Title: SLC33A1 exports oxidized glutathione to maintain endoplasmic reticulum redox homeostasis

doi: 10.64898/2026.02.01.703113

Figure Lengend Snippet: a. Schematic depicting the chemical proteomic workflow for profiling oxidized cysteines. Cells are treated with N-ethylmaleimide (NEM) before lysis and Iodoacetamide (IAM) after lysis to alkylate the reduced cysteines and GSH. Oxidized cysteines are reduced by Tris(2-carboxyethyl) phosphine (TCEP) before being labeled with iodoacetamide-desthiobiotin (IA-DTB) and enrichment via streptavidin agarose beads for further tandem mass tag (TMT) labeling and LC/LC-MS/MS/MS analysis. b. Bar graph representing the percent of proteins within indicated organelles showing higher than 1.5-fold difference (log 2 ) in reactivity of oxidized cysteines from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. c. Fold change (log 2 ) in oxidized cysteine reactivity of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control compared to those expressing SLC33A1 cDNA. Dark red and light red mark cysteine residues with ≥2-fold and ≥1.5-fold reactivity changes compared to protein expression, respectively. Grey marks unchanged cysteines. Green marks protein expression. Data are median values for n = 2 (or more) independent cysteine reactivity profiling experiments and n = 1 independent unenriched proteomics experiments. Each biological independent experiment had 2-3 technical replicates for each condition. d. Immunoblot analysis of 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid (AMS) modified proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were reduced with 10 mM DTT or oxidized with 5 mM diamide for 5 minutes prior to treatment with 25 mM NEM for 10 minutes before lysis. The bands of oxidized and reduced proteins are labeled. e. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control (EV), WT or 2YA mutant SLC33A1 cDNAs. f. Immunoblot analysis of indicated proteins from SLC33A1 knockout HEK293T cells expressing an inducible cyto-GshF (icyto-GshF) complemented with a vector control WT or 2YA mutant SLC33A1 cDNA treated with 1 µg/ml doxycycline for 48 hours. g. Heatmap of fold change (log 2 ) in unfolded protein response (UPR) target mRNAs from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA comparing cells treated with tunicamycin to DMSO. Cells were treated with DMSO or 10 ng/ml tunicamycin (TM) for 8 hours before RNA extraction. h. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA. Cells were treated with 20 ng/ml tunicamycin for indicated time. i. Left, percent of cell number from Slc33a1 knockout KPK cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Right, percent of cell number from SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA treated with DMSO or tunicamycin for 4 days under indicated concentrations. Numbers under tunicamycin treatment were normalized to DMSO untreated. j. Relative metabolite abundance of indicated whole cell or ER metabolites from Slc33a1 knockout KPK cells expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la . k. Immunoblot analysis of indicated proteins from Slc33a1 knockout KPK cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting Ero1la. l. Left, CRISPR gene scores in SLC33A1 knockout HEK293T cells expressing a vector control or SLC33A1 cDNA cultured for 14 doublings. Top scoring hits color-coded. Pearson correlation coefficient, two-sided. Right, top-scoring genes that sensitize cells to SLC33A1 loss. m. Percent of cell number from SLC33A1 knockout HEK293T cells complemented with a vector control or SLC33A1 cDNA expressing a sgRNA targeting intergenic region (sgControl) or two different sgRNAs targeting SYVN1 after 4-day proliferation. Numbers of sg SYVN1 were normalized to sgCtr. n. Schematic of GSSG export by SLC33A1 to maintain ER redox homeostasis. GSH imported into ER is oxidized to GSSG upon reducing PDI family proteins that catalyze disulfide reduction and isomerization. SLC33A1 exports GSSG into cytosol, where it is reduced back to GSH by glutathione reductase (GR).

Article Snippet: Anti-HA magnetic beads (Thermo Scientific Pierce 88837), DAPI (D1306), 4-Acetamido-4’-Maleimidylstilbene-2,2’-Disulfonic Acid (AMS, A485), N-ethylmaleimide (NEM, 23030) from ThermoFisher Scientific.

Techniques: Lysis, Labeling, Liquid Chromatography with Mass Spectroscopy, Tandem Mass Spectroscopy, Knock-Out, Expressing, Plasmid Preparation, Control, Western Blot, Modification, Mutagenesis, RNA Extraction, CRISPR, Cell Culture

Characterization and differentiation potential of hPDLCs. (A) Schematic representation of hPDLCs mechanical memory, including the experimental grouping of cells cultured on substrates with soft (So) and stiff (St) matrix stiffness to evaluate mechanical memory effects. (B) Flow cytometry identification of hPDLCs using cell surface markers (presence of mesenchymal markers CD90 and CD146 and absence of hematopoietic markers CD34 and CD45). (C) The representative images of hPDLCs lipogenic ability. (D) The representative images of hPDLCs osteogenic ability. Scale bars in (c) = 50 μm, in (d) = 200 μm.

Journal: International Dental Journal

Article Title: Matrix Stiffness-Induced Mechanical Memory of Periodontal Ligament Cell Promotes Osteogenesis in Periodontal Bone Repair

doi: 10.1016/j.identj.2025.103992

Figure Lengend Snippet: Characterization and differentiation potential of hPDLCs. (A) Schematic representation of hPDLCs mechanical memory, including the experimental grouping of cells cultured on substrates with soft (So) and stiff (St) matrix stiffness to evaluate mechanical memory effects. (B) Flow cytometry identification of hPDLCs using cell surface markers (presence of mesenchymal markers CD90 and CD146 and absence of hematopoietic markers CD34 and CD45). (C) The representative images of hPDLCs lipogenic ability. (D) The representative images of hPDLCs osteogenic ability. Scale bars in (c) = 50 μm, in (d) = 200 μm.

Article Snippet: Analogously, osteogenic differentiation was induced in 10% FBS α-MEM medium supplemented with osteogenic induction reagents (consisting of 0.1 μM/L dexamethasone, 10 mM/L β-glycerophosphate, and 50 μg/mL ascorbic acid; MP Biomedicals and Sigma, US) for 21 days.

Techniques: Cell Culture, Flow Cytometry

Primed hPDLCs exhibit different osteogenic abilities on substrates with varying stiffness. (A) Representative images of ALP staining at days 7 and 14. (B) Quantification of ALP staining area using ImageJ software. (n = 3, * P < . 05; ** P < . 01; *** P < . 001; **** P < . 0001, ns, no significance, data are described as the mean ± SD, comparisons were analyzed by two-way ANOVA adjusted by the Tukey test). (C-F) mRNA expression levels of osteogenic markers: (C) ALP, (d) COL-1, (E) OPN, and (F) RUNX2 at days 4, 7, and 14. (n = 3, * P < . 05; ** P < . 01; *** P < . 001; **** P < . 0001, ns, no significance, data are described as the mean ± SD, comparisons were analyzed by two-way ANOVA adjusted by the Tukey test). Scale bars in (a) = 200 μm.

Journal: International Dental Journal

Article Title: Matrix Stiffness-Induced Mechanical Memory of Periodontal Ligament Cell Promotes Osteogenesis in Periodontal Bone Repair

doi: 10.1016/j.identj.2025.103992

Figure Lengend Snippet: Primed hPDLCs exhibit different osteogenic abilities on substrates with varying stiffness. (A) Representative images of ALP staining at days 7 and 14. (B) Quantification of ALP staining area using ImageJ software. (n = 3, * P < . 05; ** P < . 01; *** P < . 001; **** P < . 0001, ns, no significance, data are described as the mean ± SD, comparisons were analyzed by two-way ANOVA adjusted by the Tukey test). (C-F) mRNA expression levels of osteogenic markers: (C) ALP, (d) COL-1, (E) OPN, and (F) RUNX2 at days 4, 7, and 14. (n = 3, * P < . 05; ** P < . 01; *** P < . 001; **** P < . 0001, ns, no significance, data are described as the mean ± SD, comparisons were analyzed by two-way ANOVA adjusted by the Tukey test). Scale bars in (a) = 200 μm.

Article Snippet: Analogously, osteogenic differentiation was induced in 10% FBS α-MEM medium supplemented with osteogenic induction reagents (consisting of 0.1 μM/L dexamethasone, 10 mM/L β-glycerophosphate, and 50 μg/mL ascorbic acid; MP Biomedicals and Sigma, US) for 21 days.

Techniques: Staining, Software, Expressing